Summary of findings: leflunomide + methotrexate vs methotrexate: ACR 50% improvement
Summary of findings: leflunomide + methotrexate leads to higher ACR 50 at 6 months compared with methotrexate, 6 months (high certainty).
What each review found
Include earlier review versions| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Summary of findings: leflunomide + methotrexate vs methotrexate, 6 months ACR 50 at 6 months · adult patients with rheumatoid arthritis Summary of findings: leflunomide + methotrexate leads to higher ACR 50 at 6 months compared with methotrexate, 6 months (high certainty). Leflunomide for the treatment of rheumatoid arthritis (2002) · Cochrane Headline outcomes only | RR 4.35 [2.09, 9.03] | 1 study · 263 participants | High |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Leflunomide for the treatment of rheumatoid arthritis 2002 · Cochrane Headline outcomes only | Not reported | list not extracted yet | Not assessed |
Studies behind the findings
None of these reviews ties its included studies to this outcome in the data here. Cochrane reviews and reviews with headline outcomes only do not list their studies yet.
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.